ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Terumo Corp.

Business Summary

Terumo Corp. engages in the manufacturing and sale of medical products and equipment. It operates through the following segments: Cardiac and Vascular Company, General Hospital Company, and Blood Management Company. The Cardiac and Vascular Company segment offers services and treatments including cardiac and vascular surgery and interventional therapies performed inside blood vessels. The General Hospital Company segment provides infusion and closed anticancer drug infusion systems, measuring devices system with communication functions, diabetes management, adhesion barrier, and peritoneal dialysis. The Blood Management Company segment offers a combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction. The company was founded by Shibasaburo Kitasato on September 17, 1921 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2021 JPYUSD
Gross Profit307,165M2,896.21M
Operating income97,694M921.14M
Income before tax97,776M921.91M
Net income77,267M728.53M
Diluted EPS102.100.96
Dividends Per Share290.27
Total Assets1,351.19B12,227.98M
Total liabilities494,524M4,475.33M
Total equity856,662M7,752.59M
Operating cash flow121,485M1,145.46M
Currency in JPYCurrency in USD

Historical Data

 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 514,164M 587,775M 599,481M 628,897M 613,842M
Gross Profit 261,259M 305,629M 312,203M 325,045M 307,165M
Operating income 90,547M 106,970M 100,621M 108,789M 97,694M
Income before tax 74,881M 106,630M 102,709M 106,466M 97,776M
Net income 55,002M 91,295M 79,470M 85,210M 77,267M
EBITDA 125,018M 149,005M 144,656M 161,147M 151,626M
Diluted EPS 71.37 121.03 104.96 112.61 102.10
Dividends Per Share 21 25 27 28 29
Total Assets 1,022.26B 1,081.04B 1,120.79B 1,241.35B 1,351.19B
Total liabilities 530,735M 530,606M 422,674M 486,468M 494,524M
Total equity 491,421M 550,307M 698,034M 754,813M 856,662M
Operating cash flow 82,888M 114,562M 93,571M 117,479M 121,485M
 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 4,748.13M 5,303.27M 5,405.85M 5,784.24M 5,787.82M
Gross Profit 2,412.64M 2,757.57M 2,815.31M 2,989.58M 2,896.21M
Operating income 836.17M 965.15M 907.35M 1,000.58M 921.14M
Income before tax 691.50M 962.08M 926.18M 979.21M 921.91M
Net income 507.92M 823.72M 716.62M 783.71M 728.53M
EBITDA 1,154.50M 1,344.41M 1,304.44M 1,482.14M 1,429.65M
Diluted EPS 0.65 1.09 0.94 1.03 0.96
Dividends Per Share 0.19 0.22 0.24 0.25 0.27
Total Assets 9,174.02M 10,164.97M 10,125.94M 11,498.81M 12,227.98M
Total liabilities 4,762.94M 4,989.24M 3,818.71M 4,506.21M 4,475.33M
Total equity 4,410.13M 5,174.48M 6,306.49M 6,991.92M 7,752.59M
Operating cash flow 765.44M 1,033.65M 843.78M 1,080.50M 1,145.46M

Valuation Measures

Mar 2021
Operating margin15.91%
Profit margin12.58%

Key executives

  • President, CEO & Representative Director: Shinjiro Sato
  • Chief Financial & Accounting Officer: Naoki Muto
  • Chief Clinical & Regulatory Affairs Officer: Kazuhisa Senshu
  • Chief Information Officer & Executive Officer: Katsuya Takeuchi
  • Director, Head-Compliance & Legal Affairs: Shouji Hatano


  • Nomura Asset Management Co., Ltd. (8.0%)
  • Dai-ichi Life Holdings, Inc. (4.0%)
  • Nikko Asset Management Co., Ltd. (3.9%)
  • Daiwa Asset Management Co. Ltd. (3.9%)
  • Massachusetts Financial Services Co. (3.9%)
  • Asset Management One Co., Ltd. (3.6%)
  • Meiji Yasuda Life Insurance Co. (3.2%)
  • Mitsubishi UFJ Financial Group, Inc. (2.8%)
  • Sumitomo Mitsui Trust Asset Management Co., Ltd. (2.4%)
  • The Vanguard Group, Inc. (2.2%)

Contact Details

  • Website:
  • Address: 2-44-1 Hatagaya, Shibuya-Ku, Tokyo, 151-0072, Japan
  • Phone: +81.3.3374.8111

Related Companies

  • Terumo Yamaguchi Corp.
  • Terumo BCT Japan, Inc.
  • Terumo Singapore Pte Ltd. (Yangon Branch)
  • Wego Terumo (Weihai) Medical Products Co., Ltd.
  • Terumo Taiwan Medical Co., Ltd.
  • Terumo France SAS
  • Terumo Medical Canada, Inc.
  • Terumo Restricted Stock Compensation Plan
  • Terumo China Holdings Co. Ltd.
  • Essen Technology Pte Ltd.
  • QUIREM Medical BV
  • TP Estate, Inc.
  • Terumo BCT Venezuela CA
  • Terumo BCT Portugal Unipessoal Lda.
  • Terumo Russia LLC
  • Terumo BCT Biotechnologies LLC
  • Terumo Colombia Andina SAS
  • Terumo BCT Colombia SA
  • Terumo BCT Uruguay SA
  • Terumo BCT Peru SAC
  • Terumo Panama International, Inc.
  • Terumo Mauritius Holding Ltd.
  • Terumo India Pvt Ltd.
  • Terumo BCT (Hong Kong) Ltd.
  • Terumo Medical (Shanghai) Co., Ltd.
  • Terumo Vietnam Medical Equipment Co., Ltd.
  • MicroVention Europe SARL
  • PT Terumo Indonesia
  • Terumo Singapore Pte Ltd.
  • Terumo Marketing Philippines, Inc.


  • Merit Medical Systems, Inc.
  • Fresenius SE & Co. KGaA
  • Koninklijke Philips N.V.
  • Haemonetics Corporation
  • Getinge AB Class B
  • Fresenius Medical Care AG & Co. KGaA
  • Cerus Corporation
  • Silk Road Medical, Inc.
  • Cardiovascular Systems, Inc.
  • CryoLife, Inc.
  • AngioDynamics, Inc.
  • Stryker Corporation
  • InspireMD, Inc.
  • BioCardia, Inc.
  • APT Medical Inc. Class A
  • LeMaitre Vascular, Inc.
  • LivaNova Plc
  • Lombard Medical Inc
  • CollPlant Biotechnologies Ltd
  • ABIOMED, Inc.
  • CytoSorbents Corporation
  • Penumbra, Inc.
  • Aziyo Biologics, Inc. Class A
  • T&R Biofab Co., Ltd
  • Retractable Technologies, Inc.
  • Guerbet SA
  • Cellect Biotechnology Ltd Sponsored ADR
  • EOFlow Co., Ltd.
  • Inspira Technologies Oxy B.H.N. Ltd.
  • Nephros, Inc.
Last Updated on 27 Oct, 2021

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more